vs
Side-by-side financial comparison of ASHLAND INC. (ASH) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.
ASHLAND INC. is the larger business by last-quarter revenue ($386.0M vs $369.6M, roughly 1.0× Sarepta Therapeutics, Inc.). ASHLAND INC. runs the higher net margin — -3.1% vs -111.5%, a 108.4% gap on every dollar of revenue. On growth, ASHLAND INC. posted the faster year-over-year revenue change (-4.7% vs -42.1%). Sarepta Therapeutics, Inc. produced more free cash flow last quarter ($127.6M vs $111.0M). Over the past eight quarters, Sarepta Therapeutics, Inc.'s revenue compounded faster (1.4% CAGR vs -18.1%).
Ashland, Inc., is an American chemical company headquartered in Wilmington, Delaware. The company began as an oil refinery in the city of Ashland, Kentucky, in 1924, before moving to Wilmington in 1994. The company has five wholly owned divisions, which include Chemical Intermediates and Solvents, composites, industrial specialties, personal and home care, pharmaceuticals, food and beverage, and agriculture. Until 2017, the company was the primary manufacturer of Valvoline.
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
ASH vs SRPT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $386.0M | $369.6M |
| Net Profit | $-12.0M | $-412.2M |
| Gross Margin | 27.2% | — |
| Operating Margin | -1.6% | -111.4% |
| Net Margin | -3.1% | -111.5% |
| Revenue YoY | -4.7% | -42.1% |
| Net Profit YoY | 92.7% | -359.2% |
| EPS (diluted) | $-0.26 | $-3.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $386.0M | $369.6M | ||
| Q3 25 | $477.0M | $370.0M | ||
| Q2 25 | $463.0M | $513.1M | ||
| Q1 25 | $479.0M | $611.5M | ||
| Q4 24 | $405.0M | $638.2M | ||
| Q3 24 | $521.0M | $429.8M | ||
| Q2 24 | $544.0M | $360.5M | ||
| Q1 24 | $575.0M | $359.5M |
| Q4 25 | $-12.0M | $-412.2M | ||
| Q3 25 | $31.0M | $-50.6M | ||
| Q2 25 | $-742.0M | $196.9M | ||
| Q1 25 | $31.0M | $-447.5M | ||
| Q4 24 | $-165.0M | $159.0M | ||
| Q3 24 | $17.0M | $33.6M | ||
| Q2 24 | $6.0M | $6.5M | ||
| Q1 24 | $120.0M | $36.1M |
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | 59.3% | ||
| Q2 25 | 28.5% | 70.3% | ||
| Q1 25 | 30.7% | 77.5% | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | 78.7% | ||
| Q2 24 | 34.2% | 87.6% | ||
| Q1 24 | 28.0% | 85.9% |
| Q4 25 | -1.6% | -111.4% | ||
| Q3 25 | 12.8% | -27.9% | ||
| Q2 25 | -152.9% | 22.5% | ||
| Q1 25 | 10.6% | -49.1% | ||
| Q4 24 | -44.2% | 25.3% | ||
| Q3 24 | 6.1% | 5.2% | ||
| Q2 24 | -11.2% | -0.2% | ||
| Q1 24 | 3.7% | 9.7% |
| Q4 25 | -3.1% | -111.5% | ||
| Q3 25 | 6.5% | -13.7% | ||
| Q2 25 | -160.3% | 38.4% | ||
| Q1 25 | 6.5% | -73.2% | ||
| Q4 24 | -40.7% | 24.9% | ||
| Q3 24 | 3.3% | 7.8% | ||
| Q2 24 | 1.1% | 1.8% | ||
| Q1 24 | 20.9% | 10.0% |
| Q4 25 | $-0.26 | $-3.92 | ||
| Q3 25 | $0.83 | $-0.50 | ||
| Q2 25 | $-16.21 | $1.89 | ||
| Q1 25 | $0.65 | $-4.60 | ||
| Q4 24 | $-3.50 | $1.56 | ||
| Q3 24 | $0.34 | $0.34 | ||
| Q2 24 | $0.12 | $0.07 | ||
| Q1 24 | $2.39 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $304.0M | $939.6M |
| Total DebtLower is stronger | $1.4B | $829.0M |
| Stockholders' EquityBook value | $1.9B | $1.1B |
| Total Assets | $4.5B | $3.3B |
| Debt / EquityLower = less leverage | 0.74× | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $304.0M | $939.6M | ||
| Q3 25 | $215.0M | $851.0M | ||
| Q2 25 | $207.0M | $800.1M | ||
| Q1 25 | $168.0M | $522.8M | ||
| Q4 24 | $219.0M | $1.4B | ||
| Q3 24 | $300.0M | $1.2B | ||
| Q2 24 | $399.0M | $1.5B | ||
| Q1 24 | $439.0M | $1.4B |
| Q4 25 | $1.4B | $829.0M | ||
| Q3 25 | $1.4B | $140.5M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $1.3B | $1.2B |
| Q4 25 | $1.9B | $1.1B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.9B | $1.4B | ||
| Q1 25 | $2.6B | $1.1B | ||
| Q4 24 | $2.6B | $1.5B | ||
| Q3 24 | $2.9B | $1.2B | ||
| Q2 24 | $3.0B | $1.1B | ||
| Q1 24 | $3.1B | $961.2M |
| Q4 25 | $4.5B | $3.3B | ||
| Q3 25 | $4.6B | $3.5B | ||
| Q2 25 | $4.6B | $3.7B | ||
| Q1 25 | $5.2B | $3.5B | ||
| Q4 24 | $5.2B | $4.0B | ||
| Q3 24 | $5.6B | $3.6B | ||
| Q2 24 | $5.7B | $3.4B | ||
| Q1 24 | $5.9B | $3.2B |
| Q4 25 | 0.74× | 0.73× | ||
| Q3 25 | 0.73× | 0.11× | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | 0.74× | ||
| Q3 24 | 0.47× | 1.01× | ||
| Q2 24 | 0.45× | 1.14× | ||
| Q1 24 | 0.42× | 1.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $125.0M | $131.2M |
| Free Cash FlowOCF − Capex | $111.0M | $127.6M |
| FCF MarginFCF / Revenue | 28.8% | 34.5% |
| Capex IntensityCapex / Revenue | 3.6% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $200.0M | $-307.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $125.0M | $131.2M | ||
| Q3 25 | $40.0M | $-14.6M | ||
| Q2 25 | $115.0M | $261.3M | ||
| Q1 25 | $9.0M | $-583.4M | ||
| Q4 24 | $-30.0M | $92.0M | ||
| Q3 24 | $80.0M | $-70.7M | ||
| Q2 24 | $127.0M | $14.9M | ||
| Q1 24 | $54.0M | $-242.1M |
| Q4 25 | $111.0M | $127.6M | ||
| Q3 25 | $6.0M | $-37.5M | ||
| Q2 25 | $95.0M | $229.5M | ||
| Q1 25 | $-12.0M | $-627.1M | ||
| Q4 24 | $-53.0M | $54.0M | ||
| Q3 24 | $42.0M | $-108.0M | ||
| Q2 24 | $98.0M | $-14.2M | ||
| Q1 24 | $20.0M | $-274.5M |
| Q4 25 | 28.8% | 34.5% | ||
| Q3 25 | 1.3% | -10.1% | ||
| Q2 25 | 20.5% | 44.7% | ||
| Q1 25 | -2.5% | -102.5% | ||
| Q4 24 | -13.1% | 8.5% | ||
| Q3 24 | 8.1% | -25.1% | ||
| Q2 24 | 18.0% | -3.9% | ||
| Q1 24 | 3.5% | -76.4% |
| Q4 25 | 3.6% | 1.0% | ||
| Q3 25 | 7.1% | 6.2% | ||
| Q2 25 | 4.3% | 6.2% | ||
| Q1 25 | 4.4% | 7.1% | ||
| Q4 24 | 5.7% | 6.0% | ||
| Q3 24 | 7.3% | 8.7% | ||
| Q2 24 | 5.3% | 8.1% | ||
| Q1 24 | 5.9% | 9.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | 1.33× | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | 4.71× | -2.10× | ||
| Q2 24 | 21.17× | 2.31× | ||
| Q1 24 | 0.45× | -6.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
SRPT
| Pmo Products | $202.5M | 55% |
| Elevidys | $110.4M | 30% |
| Other | $56.7M | 15% |
